Follows adults with blood cancers in Languedoc-Roussillon over time
Records clinical and lab data from adults with blood cancers over time.
Plain-language title generated from the registry record
Registry title: Prospective Cohort With Hemopathy in Languedoc-Roussillon
Key facts
- Where
- Montpellier, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are being checked for a suspected blood cancer, or who were diagnosed with one less than 6 months ago.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Suspected malignant hemopathy (blood cancer) that needs further testing, or a diagnosis made less than 6 months before signing consent.
- Earlier treatment
- People who have already received treatment for a blood disease cannot join.
Main reasons for not taking part
- Minors, or adults under legal protection
- Already treated for a blood disease
- No signed informed consent
- Not affiliated with a social security scheme
Read by machine on 12 November 2026.
Where in France
- Hematology department - UHMontpellier Saint éloiMontpellier, FranceContact: Valerie ROUILLETaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Montpellier
- Trial code
- NCT02134574
- Record updated
- 22 June 2026
- Original description
Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.Read full original descriptionShow less
Prospective Cohort Study of Clinical and Laboratory Data of Patients With Hemopathy in Languedoc-Roussillon
Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.
Inclusion: Age over 18; Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent; Having signed an informed consent; Affiliated with a social security scheme.
Exclusion: Patients who have received treatment for hematological pathology; Minor or major protected.